newdrugapprovals.org
Lilly and Incyte Corp, investigational JAK inhibitor Baricitinib for rheumatoid arthritis
Baricitinib NDA submitted jan 2016 2-[1-ethylsulfonyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]azetidin-3-yl]acetonitrile, 3-Azetidineacetonitrile, 1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-…